Changes in Macular Oedema by Optical Coherence Tomography in Patients Receiving Intravitreal Bevacizumab: A Retrospective Observational Hospital Based StudyCorrespondence Address :
Dr. Nimisha Lahkar,
Junior Resident, Department of Ophthalmology, Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Sangli, Maharashtra, India.
Introduction: Collection of fluid in the macula is called macular oedema. It is a manifestation of various pathologies main being diabetic retinopathy. Since the burden of the disease is immense and can cause blindness, its early detection and treatment are of utmost necessity. Optical Coherence Tomography (OCT) is a fast, efficacious and easy diagnostic tool for detecting macular oedema at the earliest and hence is used widely now. Intravitreal Injection Bevacizumab (IVB) is an anti Vascular Endothelial Growth Factor (anti-VEGF) agent effective in the treatment of macular oedema and is cost effective compared to its contemporaries.
Aim: To study the clinical effectiveness of IVB as measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) changes in macular thickness in patients with macular oedema.
Materials and Methods: This was a retrospective analysis of 32 eyes of 30 patients with macular oedema due to various retinal pathologies that underwent IVB and followed-up for a period of six months. The outcomes were measured on SD-OCT at baseline then at one month, three months and six months. Morphological changes were also analysed through the OCT pictures. Paired t-test and chi-square test were used for statistical analysis.
Results: The Central Foveal Thickness (CFT) reduced from 445.28±155.87 μm at baseline to 334.44±100.42 μm at one month which was statistically significant (p<0.0001) and the Parafoveal Thickness (PFT) reduced from 452.70±131.95 μm at baseline to 353.09±100.92 μm at one month which was also statistically significant (p<0.0001). This decrease in macular oedema continued at three months and six months follow-up. The improvement in visual acuity was also significant from baseline to one month and six months follow-up. Sixteen eyes (50%) received a second injection and 9 (28.12%) eyes received a third injection as well. None of the patients showed serious ocular and systemic side-effects of the drug in the present study. Along with the retinal thickness, morphological changes in OCT biomarkers namely cystoid spaces, Hyper-Reflective Foci (HRF), Serous Macular Detachment (SMD) and Ellipsoid Zones (EZ) were also analysed at baseline then at one, three and six months follow-up.
Conclusion: IVB has promising morphometric and functional outcomes in macular oedema of various retinal pathologies as a primary treatment modality in real world scenario.
Diabetic retinopathy, Ellipsoid zone, Retinal vein occlusion, Visual acuity
Date of Submission: Mar 12, 2020
Date of Peer Review: Apr 01, 2020
Date of Acceptance: Apr 09, 2020
Date of Publishing: Jun 01, 2020
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Mar 12, 2020
• Manual Googling: Apr 08, 2020
• iThenticate Software: May 22, 2020 (13%)
ETYMOLOGY: Author Origin
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)